Imagine being told you have a devastating disease, but not knowing how far it's progressed or what the future holds. This is the stark reality for many Alzheimer’s patients in the UK, where diagnosis and staging of the disease lag far behind other European countries. But here’s where it gets even more alarming: without accurate staging, patients are missing out on groundbreaking treatments that could slow the disease’s relentless march.
While a new generation of drugs has been proven to halt Alzheimer’s progression in its early stages, most UK patients are diagnosed too late to benefit. Shockingly, only two-thirds of dementia patients in the UK receive a formal diagnosis, and fewer than one in ten undergo staging—a critical process that determines the disease’s severity. This means thousands are left in the dark, unable to access treatments like donanemab and lecanemab, which target toxic brain proteins to slow cognitive decline.
And this is the part most people miss: staging isn’t just about medical treatment. It’s about giving patients and their families clarity, allowing them to plan for the future, from social care to financial arrangements. As Dr. Emily Pegg from Eli Lilly points out, failing to stage Alzheimer’s is akin to diagnosing cancer without specifying its type or stage—unthinkable in oncology, yet all too common here.
The UK’s diagnostic gap is glaring. Just 5% of Alzheimer’s patients receive biomarker-confirmed diagnoses, the lowest rate among major European nations. In contrast, Italy, Germany, and Spain offer biomarker testing to 30%, 20%, and 20% of patients, respectively. These tests, including advanced PET scans and spinal fluid analysis, are essential for pinpointing the disease’s progression.
Charities are urging the NHS to invest in diagnostic equipment, but progress is slow. Meanwhile, families like Paul Lindsay’s are paying the price. Paul’s father, Richard, waited four years for a diagnosis, only to be told he had Alzheimer’s without any staging. “We couldn’t understand if interventions were possible or where he was in his journey,” Paul recalls. His mother, unprepared for her role as a carer, watched her husband’s independence slip away. “He’s been cheated,” Paul says, “when early treatment could have slowed this down.”
But here’s the controversial question: Is the UK’s failure to prioritize Alzheimer’s staging a matter of resources, awareness, or systemic neglect? Michelle Dyson of the Alzheimer’s Society calls dementia the UK’s biggest killer, yet over a third of patients remain undiagnosed. Even those diagnosed wait an average of three years—three years without answers, support, or treatment.
Staging, Dyson argues, is the key to earlier, more accurate diagnoses. Nine out of ten people say a diagnosis made a difference, yet the UK’s approach remains fragmented. And this is where you come in: Do you think the NHS should prioritize funding for Alzheimer’s diagnostics? Or is the issue more complex, tied to broader healthcare challenges? Share your thoughts in the comments—let’s spark a conversation that could change lives.
